{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/sore-throat-acute/prescribing-information/clarithromycin-erythromycin/","result":{"pageContext":{"chapter":{"id":"d99bdb44-8580-5ebb-a68b-3a1e1f822b8e","slug":"clarithromycin-erythromycin","fullItemName":"Clarithromycin and erythromycin","depth":2,"htmlHeader":"<!-- begin field be135441-1bc7-49ad-8849-347eb329e7be --><h2>Clarithromycin and erythromycin</h2><!-- end field be135441-1bc7-49ad-8849-347eb329e7be -->","summary":"","htmlStringContent":"<!-- begin item 99da3051-9ed9-495c-ba43-f71a94ceea85 --><!-- end item 99da3051-9ed9-495c-ba43-f71a94ceea85 -->","topic":{"id":"b9203bc1-aec0-515e-b8a8-df5fbd75f255","topicId":"a235ee81-d6c7-4837-95b1-fc8ac97489f1","topicName":"Sore throat - acute","slug":"sore-throat-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"81404cee-5cce-5697-afc1-b29dbea3cf99","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"7b8dd3db-314e-5c48-8169-957babf68c00","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"3f5b8783-adcd-5d7a-9330-002285fe81e4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ecd64c56-4cd5-5be5-a040-00612d411a68","slug":"changes","fullItemName":"Changes"},{"id":"11abf9ad-d544-577d-a891-c5a379708aed","slug":"update","fullItemName":"Update"}]},{"id":"55736356-174b-57ec-a949-beb91d4a0588","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f4a572be-4b7a-5dd2-831f-2dd322766a65","slug":"goals","fullItemName":"Goals"},{"id":"7468eca7-2a8b-5d28-a756-280ec1cd0464","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2da6717d-60e3-58be-9fe4-0fc22ae6d4d7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d29c6cc4-23ef-5837-940d-d890d90aa33f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8818b707-787c-51f1-9007-fecb6a288a42","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"1e00743e-81b9-5ac8-b01f-4420d8c68b7f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"39107ffb-18a4-5a9d-8131-c82505adb09c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d58cc01b-2d33-5685-91a3-e9d59574c64d","slug":"definition","fullItemName":"Definition"},{"id":"a6fba973-e2b5-5eb0-a063-1bb336822fd0","slug":"causes","fullItemName":"Causes"},{"id":"793adffe-ef81-5f79-ab01-6c897d35ec86","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7d076a78-65a8-52bf-afc2-f4a0d24ce69b","slug":"complications","fullItemName":"Complications"},{"id":"7e75d866-d16d-54e5-abdc-52799a96b2fd","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"94a90a22-6b78-544b-98f0-8f49469d7022","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a65f2b2d-ebde-518c-8aff-0bf46dde42ad","slug":"diagnosing-the-cause","fullItemName":"Diagnosing the cause"}]},{"id":"6b54d469-8077-579a-aad8-21a2ab946d6d","fullItemName":"Management","slug":"management","subChapters":[{"id":"a51c56c5-9d90-5194-8d4c-0433122f7ee8","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"5bc31f90-4751-5459-b9e5-7dbb124672e5","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9e06b9f3-0d6a-5349-88a2-1a419eb8bbc7","slug":"paracetamol-ibuprofen","fullItemName":"Paracetamol and ibuprofen"},{"id":"d99bdb44-8580-5ebb-a68b-3a1e1f822b8e","slug":"clarithromycin-erythromycin","fullItemName":"Clarithromycin and erythromycin"},{"id":"f21e5d05-51a3-5269-89a7-1cd1dfa352c1","slug":"phenoxymethylpenicillin","fullItemName":"Phenoxymethylpenicillin"}]},{"id":"9c3bce6b-ef05-5894-b906-ebccbff4fff7","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"9642452f-8502-5e85-9e59-8aea1e5a9996","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"579fc7ee-bad3-53f9-a1f1-b2412d296c59","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"2807a9ce-d5d7-5d5b-9a3d-cb18d70b51a0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"91281f6e-4047-5b51-8bfb-1db3fc6e5b25","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3fadc0e8-a0b9-5471-b119-9c8264f2d302","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"243cf86e-53bf-5d72-8adc-a551dbece129","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4f26f8fe-168a-5d87-8f26-59783d95e902","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5bc31f90-4751-5459-b9e5-7dbb124672e5","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"40bc2e97-d4d6-5eb7-85c6-2f55e21cdf4b","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field dc4d0fda-6fef-4319-92ee-a79400ac674d --><h3>Contraindications and cautions</h3><!-- end field dc4d0fda-6fef-4319-92ee-a79400ac674d -->","summary":"","htmlStringContent":"<!-- begin item 3fc4699a-7371-4876-a5d4-a79400ac6010 --><!-- begin field d9624409-3ba6-47b6-a34e-a79400ac674d --><ul><li><strong><span id=\"cke_bm_1822S\"> </span>Do not prescribe clarithromycin or erythromycin to people at risk of QT prolongation, including:</strong><ul><li>People taking drugs that prolong the QT interval (for example haloperidol, sotalol, terfenadine, and pimozide).</li><li>People with hypokalaemia — due to the risk of prolongation of the QT interval.</li><li>People with a history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de pointes.<ul><li>Macrolides can prolong the QT interval.</li></ul></li></ul></li><li><strong>Do not prescribe clarithromycin to people with severe hepatic impairment in combination with renal impairment.</strong></li><li><strong>Do not prescribe erythromycin to people with porphyria.<span id=\"cke_bm_1822E\"> </span></strong></li><li><strong>Prescribe clarithromycin and erythromycin with caution to people with:</strong><ul><li><strong>Myasthenia gravis</strong> — macrolides may aggravate weakness symptoms.</li><li><strong>Mild to moderate hepatic impairment (or people concomitantly receiving potentially hepatotoxic drugs)</strong> — clarithromycin and erythromycin are mainly excreted by the liver.<ul><li>Use half the normal dose of clarithromycin in severe renal impairment (eGFR less than 30mL/min) for a maximum duration of 14 days. Avoid Klaricid XL® (clarithromycin prolonged release once daily tablets) in people with eGFR less than 30 mL/min.</li></ul></li><li><strong>Coronary artery disease, severe cardiac insufficiency, or bradycardia (less than 50 beats per minute)</strong> — due to increased risk of QT prolongation.</li></ul></li><li><strong>Prescribe erythromycin with caution to people with moderate to severe renal impairment.</strong><ul><li>Give a maximum dose for erythromycin of 1.5 g a day in severe renal impairment due to the risk of ototoxicity.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sore-throat-acute/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sore-throat-acute/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sore-throat-acute/references/\">BNF 73, 2017</a>]</p><!-- end field d9624409-3ba6-47b6-a34e-a79400ac674d --><!-- end item 3fc4699a-7371-4876-a5d4-a79400ac6010 -->","subChapters":[]},{"id":"db0ef58d-08b9-5122-9204-2a082f1fabd0","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 5521e6f4-796f-4db0-bbf2-a79400ac9955 --><h3>Adverse effects</h3><!-- end field 5521e6f4-796f-4db0-bbf2-a79400ac9955 -->","summary":"","htmlStringContent":"<!-- begin item 371656f0-200c-4342-83b4-a79400ac9449 --><!-- begin field 89ca0e32-a9e7-4ff0-a63a-a79400ac9955 --><ul><li>Nausea, vomiting, abdominal discomfort, and diarrhoea are the most common adverse effects of macrolides.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with clarithromycin or erythromycin. Pseudomembranous colitis is an acute, exudative colitis caused by Clostridium difficile, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li>Anaphylaxis is rarely associated with clarithromycin or erythromycin.</li><li>Hepatotoxicity (including cholestatic jaundice) and rash have been reported following treatment with clarithromycin or erythromycin.</li><li>Reversible hearing loss (sometimes with tinnitus) can occur after large doses of clarithromycin (1–2 g) or erythromycin (more than 4 g).</li><li>Other adverse effects reported rarely or very rarely include pancreatitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sore-throat-acute/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sore-throat-acute/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sore-throat-acute/references/\">BNF 73, 2017</a>]</p><!-- end field 89ca0e32-a9e7-4ff0-a63a-a79400ac9955 --><!-- end item 371656f0-200c-4342-83b4-a79400ac9449 -->","subChapters":[]},{"id":"8528ed10-73a2-594d-a784-b6fd93ae570a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 66766e06-4d57-4310-acc6-a79400acd0ee --><h3>Drug interactions</h3><!-- end field 66766e06-4d57-4310-acc6-a79400acd0ee -->","summary":"","htmlStringContent":"<!-- begin item c73c1a36-597c-4de8-abbd-a79400accd33 --><!-- begin field 94a342bd-0052-4d39-b5f8-a79400acd0ee --><p><strong>Drug interactions with clarithromycin and erythromycin include:</strong></p><ul><li><strong>Carbamazepine</strong> — clarithromycin and erythromycin inhibit the cytochrome P450 enzyme CYP3A4, resulting in reduced carbamazepine metabolism.<ul><li>Reduce the dose of carbamazepine by 30–50% during treatment with clarithromycin or erythromycin.</li><li>Advise the person to report symptoms of carbamazepine toxicity (such as dizziness, diplopia, ataxia, or confusion).</li></ul></li><li><strong>Rivaroxaban </strong>— erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Warfarin</strong> — occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Statins</strong> — there is an increased risk of myopathy (due to cytochrome P450 enzyme CYP3A4 inhibition) if clarithromycin or erythromycin are taken with simvastatin or atorvastatin.<ul><li>For simvastatin —concurrent use with clarithromycin or erythromycin is contraindicated as simvastatin is extensively metabolized by CYP3A4. If treatment with clarithromycin cannot be avoided, stop treatment with simvastatin during the course of treatment.</li><li>For atorvastatin, avoid concurrent use with clarithromycin or erythromycin, as atorvastatin is moderately metabolised by CYP3A4. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (10 mg), and advise the person to report any muscle pain, tenderness, or weakness.</li><li>Clinically significant drug interactions resulting from cytochrome P450-mediated metabolism are not expected for rosuvastatin and pravastatin as they are not metabolized to a clinically significant extent by the cytochrome P450 system. Fluvastatin is not dependent on CYP3A metabolism; therefore, an interaction with clarithromycin is unlikely. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Calcium channel blockers (CCB's)</strong> — due to an increased risk of hypotension, caution is advised with the concurrent use of macrolides and CCB's metabolised by CYP3A4 (such as verapamil, amlodipine, and diltiazem).</li><li><strong>Drugs that prolong the QT interval</strong> (such as haloperidol, sotalol, terfenadine, and pimozide) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, short-acting beta-2 agonists) — hypokalaemia is a risk factor for QT prolongation.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Theophylline</strong> — Erythromycin and possibly clarithromycin increase plasma concentrations of theophylline, and theophylline may also reduce absorption of oral erythromycin.<ul><li>Check theophylline levels 48 hours after starting erythromycin, and adjust the dose of theophylline accordingly.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sore-throat-acute/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sore-throat-acute/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sore-throat-acute/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sore-throat-acute/references/\">MHRA, 2020</a>]</p><!-- end field 94a342bd-0052-4d39-b5f8-a79400acd0ee --><!-- end item c73c1a36-597c-4de8-abbd-a79400accd33 -->","subChapters":[]},{"id":"0478b7ec-5b9d-53de-a6f3-e1e32c0dfff6","slug":"dosing-information","fullItemName":"Dosing information","depth":3,"htmlHeader":"<!-- begin field b030b4de-70ae-4727-a305-a79400ace9e1 --><h3>Dosing information</h3><!-- end field b030b4de-70ae-4727-a305-a79400ace9e1 -->","summary":"","htmlStringContent":"<!-- begin item 4bdb5116-0380-4d61-804e-a79400ace603 --><!-- begin field a1f4a881-95f2-43b4-be47-a79400ace9e1 --><h4>Clarithromycin</h4><ul><li>In adults, prescribe 250 mg to 500 mg twice daily for five days.</li><li>In children, prescribe:<ul><li>7.5 mg/kg twice daily in those weighing up to 8 kg.</li><li>62.5 mg twice daily in those weighing 8 to 11 kg.</li><li>125 mg twice daily in those weighing 12 to 19 kg.</li><li>187.5 mg twice daily in those weighing 20 to 29 kg.</li><li>250 mg twice daily in those weighing 30 to 40 kg.</li><li>250 mg twice daily in children aged 12 to 17 years, increased to 500 mg twice daily in severe infections.</li></ul></li></ul><h4>Erythromycin</h4><ul><li>In pregnant women, prescribe 500 mg four times daily for five days.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sore-throat-acute/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sore-throat-acute/references/\">PHE, 2017b</a>]</p><!-- end field a1f4a881-95f2-43b4-be47-a79400ace9e1 --><!-- end item 4bdb5116-0380-4d61-804e-a79400ace603 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}